Apply to Speak

Please contact us to nominate speakers for our programs

 China has seen vigorous growths in its drug and medical devices industry. Propelled by recent changes in regulatory and funding environments, bringing new therapeutics and technologies to the China market becomes an appealing strategy for all kinds of investors. In 2017, China joined the ICH as a full regulatory member in an effort to actively promote the timely entry of international drugs into the Chinese market, and to support the innovation and competitiveness of its domestic pharmaceutical industry. In 2018, Hong Kong cleared way for pre-revenue biotech IPOs, 4 companies already listed on HKEX by Dec, 2018. Meanwhile, NMPA (Formally CFDA) continued its initiative of drug evaluation and approval systems, including optimizing clinical trial management, accelerating the evaluation and approval for marketing authorizations, and conducting new generic consistency evaluation (GCE).  The highest level of government also carried out the “4+7” pilot drug procurement scheme, further lowered cost as well as profit margin for generic drugs.

With all these changes in the air, there are numerous opportunities as well as uncertainties for both innovators and investors. We are designing our program and inviting Key Opinion Leaders in pharma industry, pioneers in cross-border transactions, and experts in regulatory, legal and financial topics to share their experiences and expertise to all participants who want to explore opportunities with China’s emerging healthcare market.

With 5+ programs in 2019, China FocusTM Team is constantly looking for potential speakers in all areas. Please contact us to nominate speakers for our programs.  Recommend a speaker.

Past Speakers

A

Aamir Shahzad

President
European Society for Translational Medicine

Ai-Min Hui (TBD)

CMO, Fosun Pharma

Alan Jiang

Chief Strategy Officer
XtalPi

Alexander Gaffney

Sr. Manager
PwC Health Research Institute

Andy Li

Founding Partner
Biosense Global LLC


Anjiang (Vincent) Liu

Senior Advisor, Fosun Pharma

Anna Vardanyan

Executive Director, Business Development and Alliance Management

Aaron Chen

Senior Director, Global Business Development & Licensing, Oncology, Bayer Pharmaceuticals

B

Bernice Ma

Associate Principal
Evolution Road LLC

Bob Ai

Senior Vice President, Solebury Trout (Moderator)

Brad Loncar

CEO
Loncar Investments

C

Chong Xu

Senior Associate, F-Prime Capital Partners

Christian Soschner

CEO
CS Life Science Invest

Csaba Wolf

Business Development Director
Deloitte

Cynthia Cai

Senior Advisor, Northern Light Venture Capital

D

Dan Zhang

President
European Society for Translational Medicine

Danhui Wang

Managing Partner
Remedeca Partners LLC

Daniel Chai

Managing Partner, Turret Capital Management

Darren Ji

Partner, Lily Asia Ventures

Dayong Wang

VP Machine Learning
PathAI

Dennis Purcell

Founder and Senior Advisor, Aisling Capital (Moderator)

Derrick Li

Head of Strategy and Investor Relations
Cellular Biomedicine Group

Dianna Qian

Partner
Pivotal bioVenture Partners China

Dong Chen

Director and China head of business development
Jiangsu Hengrui Pharmaceutical

E

Echo Hindle-Yang

CEO & Founder
MSQ Ventures

Emmanuel Fobum

Global commercial strategy and Digital Innovation Leader
Johnson & Johnson

Eric Wu

Director of Business Development
ReiStone Biopharma

F

Fei Tian

Principal
Vesalius Biocapital

Feng Tian

Chief scientific Officer, Ambrx

G

Gunjan Bhardwaj

CEO
Innoplexus AG

Gordon Freeman

Professor of Medical Oncology
Dana-Farber Cancer Center/Harvard Medical School

Gottfried Köhler

Chair, Advisory board
European Society for Translational Medicine

Greg Caressi

SVP, Transformational Health
Foster & Sullivan

Ginger Ding

Director of Research, MyBioGate

H

Haishan Xiong

Senior VP Business Development
FMD K&L

Harvey Lodish

Founding Member and Professor
Whitehead Institute of Biomedical Research/MIT

Herwig Janssen

VP, Licensing & Acquisitions Emerging Markets
Janssen Pharmaceutica

Hua Mu

Chief Medical Officer
Simcere Pharmaceutical Group

I

Irene Hong

Founding Partner, CEC Capital Group

J

Jack Wu

Head of Business Development (USA)
Adlai Nortye Biopharma

James Lee

Senior business development manager
Atomwise

James Warr

Associate
Greenhill & Co.

James Huang

Managing Partner, KPCB China

Jianming Zhao

Deputy Division Director
Hangzhou Municipal Investment Promotion Bureau

Jiawen Han

Head of Business Development (USA)
Qilu Pharmaceutical

Jie (Jay) Liu

Managing Director
Torreya Partners

Jimmy Hao

Partner
Fox Rothschild LLP

Jinming Gu

Head of Biologics Development at Abpro labs;
Former Executive Director of Biologics Discovery at Shanghai HengRui Pharmaceuticals

John Chen

Director of Business Development, Livzon Mabpharm, Inc

John Xu

CEO and co-founder
Jemincare Therapeutics

Jun Bao

President and CEO
Impact Therapeutics

K

Katherine Andersen

Head of U.S. Life Science & Healthcare Relationship Banking
Silicon Valley Bank

Katherine Cohen

Venture Partner
Panacea Venture

Kim Nearing

Managing Director, Cedrus Group

Konstantin Poukalov

Perceptive Advisors

L

Laura Benjamin

President and CEO
Oncologie

Lei (Geffrey) Gao

Executive VP/Deputy General Manager
Harbin Pharma

Lijun Wu

CSO
Fosun Pharma US

Lily Zou

CEO
Fosun Pharma USA

Linda Ji

Partner, McDermott Will & Emery LLP

Lynn Yang

Managing Director, Sequoia Capital China

M

Mark Tang

Managing Director
Good Health Capital

Mark Young

Co-founder & Managing Partner
Bridge Point Capital

Martin Dueñas

Founder & CEO
OniX

Michael Song

Sr. Manager
MedImmune

Michelle Chen

VP, Head of Corporate Development
WuXi Biologics

Miguel Forte

CEO, Zelluna Immunotherapy;
Chair, Commercialization Committee at ISCT

N

Nissi Darvish

Senior Managing Director, OrbiMed

Noel Goddard

Principal, Accelerate NY Seed Fund

O

Olivier Reinhard

VP, BD&L for China and emerging markets
Sanofi

P

Ping Cao

VP business development
Henlius Biotech

Q

Qingping Zeng

President and CEO
Fosun Orinove

Qingxi (Charles) Wang

Executive President of International Division and Business Development, Executive Director of the Board
CSPC Pharmaceutical Group Ltd.

Qun Dang

VP Global head of business development, Qilu Pharmaceutical

Qiang Lu

Chairman, Genfleet Pharmaceutical

R

Rachel Sha

VP, Digital Business Development
Sanofi

Rebecca Robbins

Business Reporter, STAT News

S

Samuel Murphy

VP and Head of International BD
Salubris Pharmaceuticals

Sara Chen

Head of business development
Genfleet Therapeutics

Scott Liu

CEO, Henlius

Sean Fu

President
Luye Boston R&D LLC

Simon Xu

3D Medicines Inc

Stefanos Theoharis

SVP Corporate Development and Partnering, Cell Medica

T

Tom Du

Medical Partner
Shenzhen Share Capital

Travis McCready

President & CEO, Massachusetts Life Sciences Center

Tim Xiao

Principal at Delos Capital

W

Wei (William) Cao

CEO, Gracell Biotechnologies

Weigang Wang

Senior Director, Global Pharma Business Development & Licensing, Chia Tai Tianqing Pharmaceutical

Weimin Tang

Head of Global business & Executive VP
I-Mab Biopharma

Weiwei Liang

Associate Director BD&L
Sandoz/Novartis

Wendy Pan

Partner
Sidley Austin LLP

X

Xiangbin (Shawn) Xu

Executive Director
Simcere Innovation, Inc.

Xiangyang (Sean)

CEO
Hengrui Therapeutics

Xi-Yong (Sean) Fu

President
Luye Boston R&D LLC

Y

Yuanhua Ding

Head of External R&D, Pifzer

Z

Zengjun (Alex) Xu

Chief Scientist

CDE/NMPA

Zonghai Li

CEO&CSO, CARsgen Therapeutics

Zhaolong Gong

CEO, 3D Medcare

Zhenhua Wu

CEO, NeuExcell Therapeutics